Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921707 | 1.00 | USP7 (0.41) | USP7MEN1KMT2ASTSFNTA | |
| SCHEMBL23921842 | 0.91 | FNTA (0.42) | MEN1KMT2ASTSFNTAFNTB | |
| SCHEMBL23911248 | 0.87 | USP7 (0.43) | USP7HPGD | |
| SCHEMBL23910885 | 0.86 | STS (0.48) | MEN1KMT2ASTSFNTAFNTB | |
| SCHEMBL23910793 | 0.85 | MEN1 (0.39) | MEN1KMT2ASTSRECQLKDM4E | |
| SCHEMBL23911385 | 0.84 | USP7 (0.45) | USP7HPGD | |
| SCHEMBL23911381 | 0.84 | USP7 (0.45) | USP7HPGD | |
| SCHEMBL23921771 | 0.82 | CNR1 (0.42) | MEN1KMT2ASTSFNTAFNTB | |
| SCHEMBL23910812 | 0.82 | MEN1 (0.37) | MEN1KMT2ASTSRECQLKDM4E | |
| SCHEMBL24813008 | 0.81 | USP7 (0.59) | USP7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885MEN1 3693/4885KMT2A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.